Clinical Trials Logo

Colorectal Carcinoma clinical trials

View clinical trials related to Colorectal Carcinoma.

Filter by:

NCT ID: NCT00485316 Completed - Clinical trials for Colorectal Carcinoma

Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma

Start date: September 1993
Phase: Phase 3
Study type: Interventional

The aim of the investigators' randomized trial is to compare the short-term clinical outcome and survival between laparoscopic-assisted and open resection of colorectal carcinoma.

NCT ID: NCT00478634 Completed - Colorectal Cancer Clinical Trials

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Start date: May 2007
Phase: Phase 1
Study type: Interventional

This study will assess the safety of RAD001 when given together with cetuximab and irinotecan

NCT ID: NCT00437268 Completed - Colorectal Cancer Clinical Trials

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.

NCT ID: NCT00405587 Completed - Malignant Melanoma Clinical Trials

Safety Study of PLX4032 in Patients With Solid Tumors

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic mutation.

NCT ID: NCT00362102 Completed - Clinical trials for Colorectal Carcinoma

A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

Start date: October 2005
Phase: Phase 2
Study type: Interventional

To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have failed (progressive disease or intolerance) previous oxaliplatin-based and fluoropyrimidine-based chemotherapies.

NCT ID: NCT00305188 Completed - Clinical trials for Colorectal Neoplasms

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Start date: December 2005
Phase: Phase 3
Study type: Interventional

Primary Objective : Compare the risk of occurrence of Grade3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin between treatment group and placebo group. Main Secondary Objective : Compare the response rate (RR) between treatment group and placebo group in order to ensure that the efficacy of the chemotherapy is not compromised by the addition of xaliproden to the chemotherapeutic regimen. Other Secondary Objectives : study of the neurotoxicity parameters (Duration of oxaliplatin-induced PSN (G2,3,4); overall incidence of PSN during treatment; dose of onset of PSN ; incidence of dose-reduction and dose delay due to PSN; incidence of oxaliplatin treatment discontinuation due to PSN; change in Nerve Conduction Studies (NCS)) ; study of the safety profile (other than PSN) ; study of the chemotherapy efficacy (progression free survival, overall survival).

NCT ID: NCT00272051 Completed - Clinical trials for Colorectal Neoplasms

XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Start date: July 2002
Phase: Phase 3
Study type: Interventional

Purpose of the trial is to evaluate the efficacy of Xaliproden in reducing the neurotoxicity of the Oxaliplatin and 5-FU/LV chemotherapy, in patients with metastatic colorectal carcinomaPrimary objectives : Compare the risk of occurence of grade 3-4 peripheral sensory neuropathy relative to the cumulative dose of Oxaliplatin between treatment group and placebo group ; Compare the response rate between treatment group and placebo group.Secondary objectives : neurotoxicity parameters (overall incidence, time and dose to onset, time to recovery, change in the sensory action potentials) ; antitumoral efficacy (progression-free survival, overall survival) ; safety profile.

NCT ID: NCT00179348 Completed - Depression Clinical Trials

Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer

Start date: February 8, 2001
Phase: N/A
Study type: Interventional

This clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.

NCT ID: NCT00176774 Completed - Clinical trials for Colorectal Carcinoma

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

Start date: February 2001
Phase: Phase 2
Study type: Interventional

This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer. This is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. The purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.

NCT ID: NCT00107861 Completed - Clinical trials for Colorectal Carcinoma

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Start date: May 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: - to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; - help determine whether the virus carrying the interferon-beta gene will enter the bloodstream and liver tumor cells and cause the cancer cells to die.